[ad_1]
The European Medicines Company has acquired an utility for conditional advertising and marketing authorization for the coronavirus vaccine developed by Novavax, the EU regulator announced at present.
The shot is the primary protein-based vaccine to be assessed by the EMA. The regulator stated that it might decide “inside weeks” as a result of it had already began a rolling evaluation of the scientific information backing the vaccine in February this 12 months.
Novavax submitted its authorization request in October to the U.Ok.’s regulator, the Medicines and Healthcare merchandise Regulatory Company. And, earlier this month, Indonesia turned the first country to approve the vaccine.
Protein-based vaccines could be saved in a standard fridge, making them a substitute for dearer photographs that require ultra-cold chain storage and distribution. However the U.S. firm has reportedly faced manufacturing difficulties, which have hampered its broader efforts to scale up manufacturing.
[ad_2]
Source link